Wells Fargo
CGTX icon

Wells Fargo’s Cognition Therapeutics CGTX Stock Holding History

Wells Fargo’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.45K Sell
3,000
-50
-2% -$59 ﹤0.01% 6290
2026
Q1 		$2.32K Buy
3,050
+50
+2% +$58 ﹤0.01% 6234
2025
Q4 		$4.05K Sell
3,000
-1,000
-25% -$1.62K ﹤0.01% 6136
2025
Q3 		$5.4K Buy
4,000
+3,000
+300% +$4.09K ﹤0.01% 6063
2025
Q2 		$310 Hold
1,000
– – ﹤0.01% 6417
2025
Q1 		$421 Hold
1,000
– – ﹤0.01% 6278
2024
Q4 		$701 Hold
1,000
– – ﹤0.01% 6291
2024
Q3 		$469 Hold
1,000
– – ﹤0.01% 6176
2024
Q2 		$1.66K Buy
1,000
+854
+585% +$1.7K ﹤0.01% 6044
2024
Q1 		$266 Buy
146
+10
+7% +$21 ﹤0.01% 6431
2023
Q4 		$252 Buy
136
+8
+6% +$11 ﹤0.01% 6548
2023
Q3 		$184 Sell
128
-9
-7% -$14 ﹤0.01% 6607
2023
Q2 		$251 Buy
137
+13
+10% +$28 ﹤0.01% 6636
2023
Q1 		$246 Sell
124
-38,386
-100% -$73.1K ﹤0.01% 6720
2022
Q4 		$80.9K Sell
38,510
-38,417
-50% -$77.6K ﹤0.01% 4638
2022
Q3 		$146K Buy
76,927
+60
+0.1% +$125 ﹤0.01% 4411
2022
Q2 		$162K Buy
76,867
+76,843
+320,179% +$199K ﹤0.01% 4393
2022
Q1 		$0 Hold
24
– – ﹤0.01% 7116
2021
Q4 		$0 Buy
+24
New +$234 ﹤0.01% 7261

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Wells Fargo's CGTX Position: Q2 2026 in Review

Wells Fargo reduced its Cognition Therapeutics (CGTX) stake by 1.6% in Q2 2026, selling an estimated $59 and leaving 3,000 shares worth $3.45K. The position accounts for ﹤0.01% of the portfolio, ranked #6290.

Wells Fargo first reported a position in CGTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $162K in Q2 2022. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Wells Fargo held 3,000 shares of Cognition Therapeutics worth $3.45K as of Q2 2026.
  • Wells Fargo sold 50 Cognition Therapeutics shares in Q2 2026, an estimated $59.
  • Cognition Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6290 holding.
  • Wells Fargo first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Wells Fargo's Cognition Therapeutics position peaked at $162K in Q2 2022.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.